Immuneering is advancing a robust pipeline of novel drug programs starting with IMM-1-104, which is designed to achieve pan-KRAS/NRAS activity through deep, cyclic inhibition of MEK. This differentiated approach aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, basal level of signaling designed to spare healthy cells.

Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data in new and creative ways providing counterintuitive insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views.